MWE China Law Offices and its strategic alliance partner McDermott Will & Emery are proud to co-host our annual Shanghai Life Sciences Forum in partnership with the Redefining Early Stage Investments (RESI) conference.
This...more
10/30/2019
/ Acquisitions ,
Corporate Governance ,
Cross-Border Transactions ,
Events ,
Foreign Investment ,
Health Care Providers ,
Investment Funds ,
Investment Opportunities ,
Investors ,
Life Sciences ,
Medical Devices ,
Mergers ,
Outbound Transactions ,
Pharmaceutical Industry ,
Popular ,
Private Equity ,
Regulatory Requirements ,
Venture Capital
Since the Trump Administration announced its tariffs on Chinese goods, the US-China trade war has continued to escalate and create uncertainty for many US, Chinese and other international companies. The Trump Administration’s...more
10/28/2019
/ Bureau of Industry and Security (BIS) ,
China ,
Criminal Liability ,
Export Administration Regulations (EAR) ,
Exports ,
Foreign Policy ,
Supply Chain ,
Tariffs ,
Technology Sector ,
Trade Relations ,
Trade Wars ,
Trump Administration ,
US Trade Policies
Data Inspections in China: Increased Supervision and Compliance -
Data protection inspections have become more frequent for companies with operations in China. Many companies are struggling for guidance on how to...more
Enforceable in all EU member states on 25 May 2018, the General Data Privacy Regulation will require action by organisations both inside and outside the European Union to ensure compliance with this far-reaching privacy legal...more
Overview of the Proposed Reforms of the EU Merger Control Regime -
In October 2016, the European Commission launched a public consultation to continue the process of identifying possible areas of the EU Merger Regulation...more
12/5/2016
/ 28 U.S.C. § 1782 ,
Acquisitions ,
Arbitration ,
Chile ,
China ,
Competition ,
Defend Trade Secrets Act (DTSA) ,
EU ,
European Merger Control Regulation ,
Foreign Investment ,
Healthcare ,
Member State ,
Mergers ,
Shareholders ,
Statute of Limitations ,
Trade Secrets
Welcome to the third issue of Focus on China Compliance for 2015. According to the FCPA Blog’s October 2015 Corporate Investigations List, China leads the countries reported to be involved in FCPA investigations with 29...more
10/29/2015
/ Aiding and Abetting ,
Air Pollution ,
Anti-Bribery ,
Anti-Corruption ,
Bribery ,
China ,
Compliance ,
Conflicts of Interest ,
Contaminated Properties ,
Cooperation ,
Corruption ,
Criminal Conspiracy ,
Criminal Prosecution ,
Data Privacy ,
Data Security ,
Death Penalty ,
Department of Justice (DOJ) ,
Embezzlement ,
Employee Privacy Rights ,
Enforcement Actions ,
Environmental Policies ,
Explosions ,
Extradition ,
Financing ,
Fines ,
Foreign Corrupt Practices Act (FCPA) ,
Hazardous Waste ,
Individual Accountability ,
Internal Controls ,
Internal Investigations ,
Joint Tortfeasors ,
Joint Venture ,
Law Enforcement ,
Multinationals ,
New Legislation ,
Permits ,
Personal Data ,
Professional Misconduct ,
Remediation ,
Risk Mitigation ,
Safety Inspections ,
Search & Seizure ,
Securities and Exchange Commission (SEC) ,
Sentencing ,
Surveillance ,
Third-Party ,
Toxic Chemicals ,
Whistleblowers ,
White Collar Crimes
In This Issue:
- Between a Rock and a Hard Place: Navigating Disclosures to U.S. Regulators Within the Framework of China’s State Secrets Law
- Internal Investigations in China: Collecting and Reviewing Digital...more
The enactment of new legislation, as well as new and continuing investigations, demonstrates that Chinese regulators have not slowed down their efforts to ferret out corruption in the pharmaceutical sector and related...more
Recently, the co-founders of a firm primarily engaged in investigation-related services were arrested in Shanghai. The arrest indicates protected information laws are being rigorously enforced in China, and could signal a...more
The Chinese Government’s wide-ranging bribery and corruption investigation into the pharmaceutical industry takes a new turn every week. Media reports contain numerous incidents of purported whistleblowers making allegations...more
The Chinese government’s recent crackdown on alleged bribery and corruption of local officials by multinational pharmaceutical companies could signal a broad trend toward elevated scrutiny of all foreign corporations...more